Medicines & Healthcare products
Regulatory Agency

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
gov.uk/mhra

[redacted]

26 October 2023

FOI 23/718

Dear [redacted]

Thank you for your information request, dated 27th September 2023, where you asked for information about the adverse reactions that have been reported for cannabis vaped liquids.

As you are aware, the Yellow Card scheme is the UK system for collecting and monitoring information about suspected safety and quality concerns regarding healthcare products and is run by the MHRA. The scheme relies on voluntary reporting by members of the public and healthcare professionals and the information provided is used in conjunction with other safety information to help the MHRA act if a concern regarding the safety, quality or efficacy of a healthcare product is identified.

The MHRA collects reports on suspected adverse drug reactions (ADRs) involving cannabis containing products, and we do accept reports for unlicensed cannabis-based products for medicinal use (CBPMs), through the scheme. A summary of this data can be viewed on our interactive Drug Analysis Profile (iDAP) for Cannabidiol and Cannabis Sativa. It is important to note that although the MHRA collects reports on unlicensed CBPMs and other unlicensed medicines supplied in the UK under a special provision, the MHRA can only take regulatory action in relation to licensed products. As of 26th October 2023, the MHRA has not received any reports relating to Cannabidiol or Cannabis Sativa preparations for vaping.

The MHRA regulates nicotine-containing e-cigarettes and e-liquids in accordance with the Tobacco and Related Products Regulations (TRPR) 2016 and, as part of this, collects and monitors information on suspected ADRs and safety concerns about these products through the Yellow Card scheme. Non-nicotine e-cigarette products are not subject to TRPR regulations and instead fall under the General

Medicines & Healthcare products
Regulatory Agency

Product Safety Regulations which are regulated by the Office for Product Safety and Standards.

I can therefore confirm that the MHRA does not hold any ADR reports that are relevant to your enquiry.

I hope the information provided is helpful. If you have a query about the information provided, please reply to this email.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk.

Please remember to quote the reference number above in any future communications.

Yours sincerely,

Safety and Surveillance group
Medicines and Healthcare products Regulatory Agency